Know when competitors begin clinical development against your reference biologics. As more biologics lose exclusivity this decade, early visibility into biosimilar development matters. A newly registered comparative or PK/PD study can provide one of the earliest public signals that a competitor has entered clinical development. Eichor monitors ClinicalTrials.gov daily and alerts you whenever a biosimilar trial matches the reference molecules you specify.
Tell us the reference biologics you want to monitor (for example, pembrolizumab, ustekinumab, or aflibercept). We'll identify matching industry biosimilar studies and provide:
Delivered by email, usually the same business day. No call, no installation, no credit card.
Public registry signals only — not a legal, patent, or freedom-to-operate opinion. Note: small-molecule generics run bioequivalence studies that are not registered, so this covers BIOSIMILARS (registered comparative trials), not ANDA generics.